logo
Plus   Neg
Share
Email

BioDelivery Sciences Gets FDA Approval For Bunavail - Quick Facts

BioDelivery Sciences International Inc. (BDSI) said Monday that it received approval of the New Drug Application or NDA for bunavail (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration or FDA.

Bunavail is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. The company expects to launch bunavail late in the third quarter of 2014.

According to the company, Bunavail is the first and only formulation of buprenorphine and naloxone for buccal (inside of the cheek) administration. The ability of bunavail to stick on the inside of the cheek, unlike sublingual products that need to be kept in place under the tongue until they dissolve, allows patients to talk, swallow and go about normal daily activities while the medication is being consistently absorbed.

The company noted that it plans to launch bunavail in late third quarter 2014 and anticipates peak sales potential of bunavail of up to $250 million in the U.S. BDSI will also begin entertaining commercial partnerships for bunavail outside of the U.S. In March 2014, BDSI announced it had entered into an agreement with Quintiles to support the launch of Bunavail.

As per terms of the agreement, Quintiles will provide a range of services to support the launch and subsequent commercialization of bunavail in the U.S., including recruiting and training a field sales force.

Separately, BDSI has entered into an agreement with Ashfield Market Access to provide managed markets and trade support for bunavail. Ashfield Market Access, which is led by industry veterans including Steve Stefano, who led GlaxoSmithKline's managed markets group for more than 20 years, will be responsible for executing a payer strategy aimed at maximizing patient access to bunavail.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bed Bath & Beyond, Inc. is planning to close around 200 mostly Bed Bath & Beyond stores over the next two years amid continuing struggles with Covid-19. The home improvement retailer, which reported a wider-than-expected loss in its first quarter with sharply lower sales, said the move is part of its plans to right-size its real estate portfolio and to cut costs. United Airlines has warned that 36,000 employees or about 45% of its U.S. workforce could be furloughed in October, due to continuing losses caused by the coronavirus pandemic and collapse in air travel, according to reports citing the company's memo sent to employees. Walmart is planning to launch a new subscription program, Walmart+, in late July, according to a report by Recode. The new membership program, which is likely to be direct competitor to Amazon Prime, will cost $98 per year. Walmart+ is expected to include fuel discounts at Walmart gas stations, unlimited same-day delivery of groceries and general merchandise from Walmart Supercenters...
Follow RTT